CYTK Historical PE Ratio image   This CYTK PE ratio history page last updated 8/8/2022
CYTK Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q2 2022
8/4/2022
46.72-0.23-0.92NA
Q1 2022
5/4/2022
41.03-1.02-4.08NA
Q4 2021
2/24/2022
33.95-0.36-1.44NA
Q3 2021
11/3/2021
36.67-0.95-3.80NA
Q2 2021
8/5/2021
30.24-0.86-3.44NA
Q1 2021
5/6/2021
23.37-0.66-2.64NA
Q4 2020
2/25/2021
19.85-0.62-2.48NA
Q3 2020
11/4/2020
18.00-0.05-0.20NA
Q2 2020
8/6/2020
21.64-0.68-2.72NA
Q1 2020
5/6/2020
16.63-0.66-2.64NA
Q4 2019
3/3/2020
14.57-0.52-2.08NA
Q3 2019
10/31/2019
11.65-0.50-2.00NA
Q2 2019
8/8/2019
13.63-0.56-2.24NA
Q1 2019
5/9/2019
9.01-0.54-2.16NA
Q4 2018
2/21/2019
7.21-0.48-1.92NA
Q3 2018
11/1/2018
6.93-0.40-1.60NA
Q2 2018
7/26/2018
7.90-0.51-2.04NA
Q1 2018
4/26/2018
7.70-0.56-2.24NA
Q4 2017
2/15/2018
8.65-0.75-3.00NA
Q3 2017
10/26/2017
12.80-0.60-2.40NA
Q2 2017
8/2/2017
15.00-0.60-2.40NA
Q1 2017
4/27/2017
17.00-0.62-2.48NA
Q4 2016
2/16/2017
11.300.160.6417.7
Q3 2016
10/27/2016
8.830.742.963.0
Q2 2016
7/28/2016
9.95-0.29-1.16NA
Q1 2016
4/28/2016
8.26-0.31-1.24NA
Q4 2015
2/16/2016
7.06-0.24-0.96NA
Q3 2015
10/29/2015
8.86-0.23-0.92NA
Q2 2015
7/29/2015
7.06-0.27-1.08NA
Q1 2015
4/30/2015
6.29-0.23-0.92NA
Q4 2014
2/12/2015
6.490.230.927.1
Q3 2014
10/30/2014
3.80-0.16-0.64NA
Q2 2014
7/30/2014
4.16-0.23-0.92NA
Q1 2014
5/6/2014
4.43-0.27-1.08NA
Q4 2013
2/6/2014
6.900.210.848.2
Q3 2013
10/30/2013
6.23-0.43-1.72NA
Q2 2013
7/31/2013
12.44-0.58-2.32NA
Q1 2013
4/30/2013
7.68-0.54-2.16NA
Q4 2012
2/5/2013
7.02-0.42-1.68NA
Q3 2012
10/30/2012
NA-0.42-1.68NA
Q2 2012
7/31/2012
4.14-0.78-3.12NA
Q1 2012
4/26/2012
6.24-0.78-3.12NA
CYTK PE History Chart
PeriodPriceGAAPTTMPE
Q2 2022
8/4/2022
46.72-0.23-2.56NA
Q1 2022
5/4/2022
41.03-1.02-3.19NA
Q4 2021
2/24/2022
33.95-0.36-2.83NA
Q3 2021
11/3/2021
36.67-0.95-3.09NA
Q2 2021
8/5/2021
30.24-0.86-2.19NA
Q1 2021
5/6/2021
23.37-0.66-2.01NA
Q4 2020
2/25/2021
19.85-0.62-2.01NA
Q3 2020
11/4/2020
18.00-0.05-1.91NA
Q2 2020
8/6/2020
21.64-0.68-2.36NA
Q1 2020
5/6/2020
16.63-0.66-2.24NA
Q4 2019
3/3/2020
14.57-0.52-2.12NA
Q3 2019
10/31/2019
11.65-0.50-2.08NA
Q2 2019
8/8/2019
13.63-0.56-1.98NA
Q1 2019
5/9/2019
9.01-0.54-1.93NA
Q4 2018
2/21/2019
7.21-0.48-1.95NA
Q3 2018
11/1/2018
6.93-0.40-2.22NA
Q2 2018
7/26/2018
7.90-0.51-2.42NA
Q1 2018
4/26/2018
7.70-0.56-2.51NA
Q4 2017
2/15/2018
8.65-0.75-2.57NA
Q3 2017
10/26/2017
12.80-0.60-1.66NA
Q2 2017
8/2/2017
15.00-0.60-0.32NA
Q1 2017
4/27/2017
17.00-0.62-0.01NA
Q4 2016
2/16/2017
11.300.160.3037.7
Q3 2016
10/27/2016
8.830.74-0.10NA
Q2 2016
7/28/2016
9.95-0.29-1.07NA
Q1 2016
4/28/2016
8.26-0.31-1.05NA
Q4 2015
2/16/2016
7.06-0.24-0.97NA
Q3 2015
10/29/2015
8.86-0.23-0.50NA
Q2 2015
7/29/2015
7.06-0.27-0.43NA
Q1 2015
4/30/2015
6.29-0.23-0.39NA
Q4 2014
2/12/2015
6.490.23-0.43NA
Q3 2014
10/30/2014
3.80-0.16-0.45NA
Q2 2014
7/30/2014
4.16-0.23-0.72NA
Q1 2014
5/6/2014
4.43-0.27-1.07NA
Q4 2013
2/6/2014
6.900.21-1.34NA
Q3 2013
10/30/2013
6.23-0.43-1.97NA
Q2 2013
7/31/2013
12.44-0.58-1.96NA
Q1 2013
4/30/2013
7.68-0.54-2.16NA
Q4 2012
2/5/2013
7.02-0.42-2.40NA
Q3 2012
10/30/2012
NA-0.42NANA
Q2 2012
7/31/2012
4.14-0.78NANA
Q1 2012
4/26/2012
6.24-0.78NANA
Quotes delayed 20 minutes

Email EnvelopeFree CYTK Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Cytokinetics (CYTK) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

DARE PE Ratio History
DAWN PE Ratio History
DBTX PE Ratio History
DCPH PE Ratio History
DCTH PE Ratio History
DERM PE Ratio History
DFFN PE Ratio History
DGX PE Ratio History
DHR PE Ratio History
DICE PE Ratio History
How should the CYTK historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Cytokinetics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this CYTK Historical PE Ratio page.

What is the average historical PE for CYTK based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The CYTK historical PE ratio using the annualized quarterly earnings method works out to 9.0.

What is the average historical PE for CYTK based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The CYTK historical PE ratio using the TTM earnings method works out to 37.7.

On this page we presented the CYTK Historical PE Ratio information for Cytokinetics' stock. The average CYTK historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 9.0. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CYTK historical PE based on this TTM earnings result method is 37.7. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CYTK historical PE result, against the recent PE: when this page was posted on 8/5/2022, the most recent closing price for CYTK had been 51.82, and the most recent quarterly earnings result, annualized, was 0.64. Meanwhile, the most recent TTM earnings summed to 0.3. From these numbers, we calculate the recent CYTK PE on 8/5/2022 based on annualized quarterly EPS was 81.0. Based on CYTK's history, that recent PE is elevated relative to the historical average, with the recent PE 800.0% higher than the historical average PE across our data set for Cytokinetics. Looking at the recent CYTK PE on 8/5/2022 based on TTM EPS, we calculate the ratio at 172.7. Based on CYTK's history, that recent PE is elevated relative to the historical average, with the recent PE 358.1% higher than the historical average PE across our Cytokinetics data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on CYTK or any other given stock, valuation analysis for CYTK can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Cytokinetics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CYTK. Thanks for visiting, and the next time you need to research CYTK Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: FBC Stock Predictions, Funds Holding NINI, Institutional Holders of NBN.

 

CYTK Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.